Key result
Study on antiplatelet therapy in clopidogrel nonresponders by CYP2C19 status is retracted by authors.
Answers are grounded in this paper and cite their sources.
Retracted findings on antiplatelet therapy in clopidogrel nonresponders should not guide care; leaves CYP2C19 role open for rigorous study.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ko et al. (2026) studied Clopidogrel nonresponse. Antiplatelet treatment was evaluated. The article comparing antiplatelet treatment in clopidogrel nonresponders with or without CYP2C19 polymorphism has been retracted at the request of the authors.
Synapse has enriched 10 related papers. Consider them for comparative context: